LITHIUM CLEARANCE MEASUREMENTS DURING RECOMBINANT INTERLEUKIN-2 TREATMENT - TUBULAR DYSFUNCTION IN MAN

被引：5

作者：

HEYS, SD

EREMIN, O

FRANKS, CR

BROOM, J

WHITING, PH

机构：

[1] Department of Surgery, Pathology University of Aberdeen, Aberdeen, Scotland

[2] Department of Chemical, Pathology University of Aberdeen, Aberdeen, Scotland

[3] EuroCetus B.V., 1105J, Amsterdam

来源：

RENAL FAILURE | 1993年 / 15卷 / 02期

关键词：

D O I：

10.3109/08860229309046152

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Renal tubular function was evaluated in nine patients undergoing recombinant interleukin 2 (rIL2) treatment for metastatic colorectal carcinoma. A lithium clearance technique was used and the activities of the lysosomal enzyme N-acetyl-beta-D-glucosaminidase were also measured in the patients' urine, before treatment, during treatment, and then 2 days and 23 days after rIL2 therapy had finished. Significant reductions in clearances of creatinine, sodium, and lithium were observed. The fractional excretions of sodium and lithium were also reduced. Twenty-three days following cessation of rIL2 treatment, there was still a significant reduction in creatinine clearance compared with pretreatment values (p < .01). The clearances of sodium and lithium were also reduced compared with pretreatment values although this did not achieve significance. The fractional reabsorption of sodium and water by the proximal nephron increased during rIL2 treatment, from 0.707 +/- 0.030 (pretreatment) to 0. 793 +/- 0.043. This increased reabsorption of sodium and water persisted, rising to 0.849 +/- 0.029, 2 days following cessation of treatment (p < .001, means +/- SEM). Twenty-three days later this had returned toward the pretreatment value, being 0. 781 +/- 0.036. The fractional reabsorption of sodium by the distal nephron was also significantly elevated, both during and 2 days after completing rIL2 treatment. Twenty-three days after cessation of rIL2, this value had returned to the pretreatment value. However, in contrast, the fractional reabsorption of water by the distal nephron demonstrated no change during rIL2 treatment, but 2 days posttreatment was significantly reduced and remained low for a further 3 weeks.

引用

页码：195 / 201

页数：7

共 19 条

[1]

Lotze M.T., Chang A.E., Seipp C.A., Simpson C., Vetto J.T., Rosenberg S.A., High dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: Responses, treatment of patients with disseminated findings, J Am Med Assoc, 256, pp. 3117-3124, (1986)

[2]

Rosenberg S.A., Lotze M.T., Muul L.M., Chang A.E., Avis F.P., Lehman S., Linehan W.M., Robertson C.N., Lee R.E., Rubin J.T., Seipp C.A., Simpson C.G., White D.E., A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone, N Engl J Med, 316, pp. 889-905, (1987)

[3]

Rosenberg S.A., Lotze M.T., Yang J.C., Aebersold P.M., Linehan W.M., Seipp C.A., White D.E., Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients, Ann Surg, 210, pp. 474-485, (1989)

[4]

Rosenberg S.A., Lotze M.T., Muul L.M., Et al., Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with meta-static cancer, N Engl J Med, 313, pp. 1485-1492, (1985)

[5]

Lotze M.T., Matory Y.L., Rayner A.A., Ettinghausen S.E., Vetto J.T., Seipp C.A., Rosenberg S.A., Clinical effects and toxicity of interleukin-2 in patients with cancer, Cancer, 58, pp. 2722-2764, (1986)

[6]

Belldegrun A., Webb D.E., Austin H.A., Steinberg S.M., White D.E., Linehan W.M., Rosenberg S.A., Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer, Ann lnt Med, 106, pp. 817-822, (1987)

[7]

Thomsen K., Lithium C., A new method for determining proximal and distal tubular reabsorption of sodium and water, Nephron, 37, pp. 217-223, (1984)

[8]

Koomans H.A., Boer W.H., Dorhour-Mees E.J., Evaluation of lithium clearance as a marker of proximal tubule sodium handling, Kidney Int, 36, pp. 2-12, (1989)

[9]

Duncan J.I., Heys S.D., Thomson A.W., Simpson J.G., Whiting P.H., Influence of the hepatic drug-metabolizing enzyme inducer phenobarbitone on cyclosporine nephrotoxicity and hepato-toxicity in renal allografted rats, Transplantation, 45, pp. 693-697, (1988)

[10]

Kozeny G.A., Nicolas J.D., Creekmore S., Sticklin L., Hano J.E., Fisher R.I., Effects of Interleukin-2 immunotherapy on renal function, J Clin Oncol, 6, pp. 1170-1176, (1988)

← 1 2 →